Atherosclerosis is considered to be a T-cell-driven disease since the interaction between resident cells, immune cells and their products has been recognized to promote the development of atheromatous plaques in the arterial walls [1]. The process of atherosclerosis evolves from a prelesional phase, which is potentially reversible, to complicated lesions characterized by the formation of a fibrous cap and vulnerable plaques, followed by possible rupture and atherothrombosis.
Programmed death-1 inhibition and atherosclerosis: Can nivolumab vanish complicated atheromatous plaques? / Gelsomino, F.; Fiorentino, M.*; Zompatori, M.; Poerio, A.; Melotti, B.; Sperandi, F.; Gargiulo, M.; Borghi, C.; Ardizzoni, A.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 29:1(2018), pp. mdx718.284-mdx718.285. [10.1093/annonc/mdx718]
Programmed death-1 inhibition and atherosclerosis: Can nivolumab vanish complicated atheromatous plaques?
Gelsomino, F.;Fiorentino, M.;Zompatori, M.;Poerio, A.;Melotti, B.;Gargiulo, M.;Borghi, C.;Ardizzoni, A.
2018
Abstract
Atherosclerosis is considered to be a T-cell-driven disease since the interaction between resident cells, immune cells and their products has been recognized to promote the development of atheromatous plaques in the arterial walls [1]. The process of atherosclerosis evolves from a prelesional phase, which is potentially reversible, to complicated lesions characterized by the formation of a fibrous cap and vulnerable plaques, followed by possible rupture and atherothrombosis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
